SKYE
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Skye Bioscience, Inc. (SKYE) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at D+ for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B+ (3.7) | D (1.3) | D- (0.7) | F (0.6) | C+ (2.6) | D+ (1.8) |
| 2026-11-07 | A- (3.9) | D- (1.1) | D- (0.8) | F (0.4) | C+ (2.7) | D+ (1.8) |
| 2026-10-31 | B+ (3.7) | D- (1.1) | D- (0.9) | F (0.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-24 | B+ (3.7) | D (1.2) | D- (0.8) | F (0.5) | C+ (2.6) | D+ (1.7) |
| 2026-10-17 | B+ (3.7) | D- (1.1) | D- (0.8) | F (0.5) | C+ (2.6) | D+ (1.8) |